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Abstract
Background: Cardiac toxicity due to ingestion of oleander plant seeds in Sri Lanka and some other South Asian 
countries is very common. At present symptomatic oleander seed poisoning carries a mortality of 10% in Sri Lanka and 
treatment of yellow oleander poisoning is limited to gastric decontamination and atropine administration. The only 
proven effective antidote is digoxin antibodies but these are not available for routine use because of the high cost. The 
main objective of this study is to investigate the effectiveness of a new and inexpensive antidote for patients with life 
threatening arrhythmias due oleander poisoning.
Method/design: We set up a randomised double blind clinical trial to assess the effectiveness of Fructose 1, 6 
diphosphate (FDP) in acute yellow oleander poisoning patients admitted to the adult medical wards of a tertiary 
hospital in Sri Lanka. Patients will be initially resuscitated following the national guidelines and eligible patients will be 
randomised to receive either FDP or an equal amount of normal saline. The primary outcome measure for this study is 
the sustained reversion to sinus rhythm with a heart rate greater than 50/min within 2 hours of completion of FDP/
placebo bolus. Secondary outcomes include death, reversal of hyperkalaemia on the 6, 12, 18 and 24 hour samples and 
maintenance of sinus rhythm on the holter monitor. Analysis will be on intention-to-treat.
Discussion: This trial will provide information on the effectiveness of FDP in yellow oleander poisoning. If FDP is 
effective in cardiac glycoside toxicity, it would provide substantial benefit to the patients in rural Asia. The drug is 
inexpensive and thus could be made available at primary care hospitals if proven to be effective.
Trial Registration: Current Controlled trial ISRCTN71018309
Background
Cardiac glycoside toxicity is the most common type of
plant poisoning in Sri Lanka and some other South Asian
countries [1-3]. At present, symptomatic cardiac glyco-
side poisoning carries a mortality rate of 10% in Sri Lanka
[1]. Cardiac glycosides inhibit the enzyme Na-K-ATPase
of the cardiac myocyte and the conducting system and
increase intracellular calcium concentrations. This rise in
intracellular calcium may be a mechanism for ventricular
arrhythmias [4]. These effects lead to increased automa-
ticity and excitability both during early and late depolar-
ization of the cardiac cell. Patients also develop very high
serum potassium concentrations as a result of inhibition
of Na-K-ATPase. Patients may develop arrhythmias and
become hypotensive. Hypotension interferes with intrac-
ellular production of ATP through glycolysis, as lactate
(produced due to anaerobic metabolism) inhibits the rate
limiting enzyme phosphofructokinase. This in turn will
further reduce the activity of Na-K-ATPase resulting in a
vicious cycle.
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FDP (CAS registry number 488-69-7; Merck mono-
graph number 4297) is a phosphorylated sugar that is a
normal physiological intermediary in glycolysis. It is pro-
duced from glucose by the action of phosphofructokinase
during glycolysis and is in turn broken down into pyru-
vate. Phosphofructokinase activity is the main rate-limit-
ing factor for ATP production from glucose under
anaerobic conditions. Given intravenously, FDP is capa-
ble of being actively transported into cells and acting as
an alternative energy source to glucose [5]. This can
increase ATP production in circumstances where phos-
phofructokinase is inhibited (for example by lactate). The
relative production of ATP is greater for FDP than glu-
cose.
FDP has also been shown to stimulate Na-K-ATPase
activity, and inhibit potassium efflux from myocardial
cells [6,7]. It is hypothesised that these mechanisms may
contribute to its activity in cardiac glycoside poisoning
where Na-K-ATPase is inhibited and extracellular potas-
sium is high. FDP also chelates ionised calcium. A
decrease in ionised serum calcium and/or cardiac uptake
of calcium may also be favourable,[8] given the high
intracellular calcium that occurs in cardiac glycoside poi-
soning.
These theoretical benefits of FDP have been shown in
an animal study done at the Mississippi School of Medi-
cine, USA. This study showed evidence of effectiveness of
FDP in dogs poisoned with a relative of the yellow olean-
der - the common or pink oleander. Cardiac arrhythmias
in dogs (6/6;100%) treated with FDP (50mg/kg IV)
reverted back to sinus rhythm within 30 minutes while
the arrhythmias in the control animals killed one animal
and did not revert over four hours in the other five at
which time they were sacrificed [7]. There was also no
rise in serum potassium in the group receiving FDP while
marked hyperkalemia occurred in the control group [7].
We conducted a small phase II study of increasing IV
bolus doses (30 to 250mg/kg) of FDP in patients with yel-
low oleander poisoning in Sri Lanka in 2006-7. The aim
of that study was to find a safe dose of FDP that might be
used to reverse cardio-toxicity. The agent was well toler-
ated with no evidence of any adverse effects attributable
to FDP at any of the doses and an apparent reduction of
around 0.5 mmol/L of potassium and 0.3mmol/L of cal-
cium in the highest FDP dose group. All these doses were
well within the range of doses used in previous human
studies for other conditions [9].
Previous Human Experience/safety profile for other 
indications
FDP has a well established safety profile in humans. It has
been administered as a component of total parenteral
nutrition (TPN) and has been used short-term in numer-
ous experimental human studies. It has generally been
shown to have favourable effects in these studies. For
example, in individuals with coronary artery disease and
heart failure, IV FDP increased cardiac work and reduced
ventricular filling pressures [10].
The minimum dose where effects have been seen is
around 25-50mg/kg [10]. Doses up to 250mg/kg IV have
been used safely as a single dose [10-13] and 750 mg/kg
IV as a cumulative dose (over 12 hours) [12]. The most
pivotal study was a dose-ranging study of FDP to reduce
ischemic injury post coronary artery bypass grafting. Five
doses between 50mg/kg and 750 mg/kg in divided doses
were tested with the optimal dose being 250mg/kg IV
given over 30 minutes [12].
FDP is an approved product in Italy - the only safety
concerns identified in the product information are a very
rare risk of hypersensitivity reactions [14]. The approved
dose range in Italy covers the doses to be used in this
study.
Methods/Design
Design
The study is a double blind randomised controlled clini-
cal trial with two parallel groups. The trials is designed to
be compliant with the CONSORT Statement [15]
Patients
All patients who present with a history of yellow oleander
poisoning will be assessed to determine if they are eligible
for the study. Those who meet the criteria will be
approached to give their written informed consent, fol-
lowing which they will be randomised (Figure 1). Patients
who do not initially meet the criteria will be reviewed
regularly and approached if they meet the inclusion crite-
ria at a later time point.
Inclusion criteria
patients who are admitted to adult medical wards, who
are over the age of 16years, and who have any of the fol-
lowing manifestations of oleander induced cardiac toxic-
ity:
• 2nd degree heart block
• 3rd Degree heart block
• Bradycardia with a heart rate of less than 40 beats/
minute
• Any rhythm with a systolic blood pressure below 80 
mm Hg
Exclusion criteria
Patients with documented ischemic or valvular heart dis-
ease, pregnant women and age under 16 years.
Patient management
Standard oleander patient management guidelines will be
followed. These are based on the national poisoning
treatment guidelines[16]. The only difference betweenGawarammana et al. BMC Emergency Medicine 2010, 10:15
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Figure 1 Trial profile.
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enrolled patients and those not enrolled will be the addi-
tion of FDP/placebo intervention.
Trial intervention and study procedures
Patients randomised to the treatment arm will be treated
with 250mg/kg loading dose of FDP (Esafosfina from Bio-
medical Foscama, Italy) over 20minutes followed by 6mg/
kg/hr for 24 hours in addition to standard care. Patients
randomised into the control arm will be treated with an
equal volume (equal to the volume of FDP in the treat-
ment arm) of 0.9% saline as a bolus and a 24 hour infu-
sion. All attending doctors and nurses will be blinded to
the treatment.
Clinical parameters such as systolic and diastolic blood
pressure will be monitored for 24 hours. A Holter moni-
tor will record the cardiac rhythm for 48 hours. All car-
diac events will be recorded. If a serious cardiac rhythm
abnormality recurs after an initial response to the bolus
(within 2 hours of a bolus), a further bolus of 250mg/Kg
of FDP (or equal volume of placebo) may be given at the
discretion of the treating physician while the infusion will
be maintained at the same rate.
Randomisation
Randomisation is done using purpose designed computer
software. The random sequence and allocation are con-
cealed prior to randomisation. The program will ran-
domise eligible patients in a 1:1 ratio. The allocation
sequences are generated and encrypted independently by
an IT consultant who has no role in patient recruitment,
treatment and assessment.
The randomization will be performed by study phar-
macists centrally. If a patient meets the inclusion criteria
and gives consent, clinical research assistants will call the
pharmacist with details such as name, hospital number
and weight of the patients. Then the pharmacist will ran-
domise the patients and prepare the placebo or active
treatments for the study team. The allocation will only be
known by the pharmacists who will have no other role in
patient management and data collection. Intention-to-
Treat analysis will be applied. That is, the analysis will
include all randomised patients in the groups to which
they were assigned, regardless of non-compliance, proto-
col deviations, withdrawal, and anything that happens
thereafter [17]
Outcomes
The primary outcome of this study is the reversion to sus-
tained sinus rhythm with a heart rate >50 bpm within 2
hours of completion of bolus.
Secondary outcomes include:
1. Death
2. Change from baseline serum potassium on the 6, 
12, 18 and 24 hour blood samples.
3. Time to revert and duration of reversion to sinus 
rhythm on the Holter monitor over the first 24 hours 
(reflecting the efficacy of bolus and infusion)
Sample size
We are planning to recruit 240 symptomatic patients with
yellow oleander poisoning admitted to Teaching Hospital,
Kurunegala and National Hospital Sri Lanka, Colombo.
In the study by Eddleston M et al [18], 2/32 (6.25%, 95%
CI 1% - 19%) patients reverted to sinus rhythm spontane-
ously after 2 hours. Second degree and third degree heart
block are markers of toxicity but may not be strong pre-
dictors of death (which may be due to myocardial toxicity
rather than atrio-ventricular conduction block). Rever-
sion to sinus rhythm is more likely with less severe sec-
ond degree block. We would ideally have a sample size
that ensured a significant number of third degree blocks
which are less likely to revert spontaneously so that the
effect of treatment in this sub-group can be seen. How-
ever, the proportions of the different grades of block are
not well quantified and thus precise estimates of power in
sub-groups are not possible.
We expect up to 15% spontaneous reversion by two
hours and believe a 40% reversion in the active treatment
arm would be clinically significant and likely to provide
strong evidence that this would translate to a mortality
benefit. This would require just 60 patients in each arm
(α = 0.05, β = 0.8, missing data/dropout 10%). To increase
the likelihood of recruiting enough patients with 3rd
degree heart block to see if the effect is observed in the
most severely poisoned patients, and to account for pos-
sible differences between centres we intend to do a study
of 120 patients in each arm.
Study hypothesis and principal comparisons
The primary outcome of the study is to investigate if the
addition of FDP (250mg/kg loading dose over 20 minutes
followed by 6mg/kg/hr for 24 hours) to routine treatment
will completely reverse serious arrhythmias within two
hours. The study will also investigate the effect of FDP on
the presence of abnormal rhythms and serum potassium
and other electrolytes over 24 hours.
Statistical Analysis
The Primary outcome (proportion with reversion to sinus
rhythm) will be compared with the chi-squared test.
Kaplan Meier curves will be constructed to demonstrate
the cumulative reversion to sinus rhythm over time. A
Cox proportional hazard model will be used to test the
overall difference in reversion to sinus rhythm between
treatments adjusted for baseline variables as necessary. A
longitudinal statistical technique known as Generalised
Estimating Equation (GEE) will be used to analyze
changes in electrolytes (e.g. potassium) over time.Gawarammana et al. BMC Emergency Medicine 2010, 10:15
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Independent data monitoring and ethics committee 
(IDMEC)
The IDMEC will conduct the interim analysis and exam-
ine primary and secondary outcomes.
We intend to do a planned interim analysis once a total
of 120 patients had been randomised (i.e. 60 in the treat-
ment arm and 60 in placebo) which may lead to modifica-
tion of or cessation of the trial as outlined below. The
IDMEC will be asked specifically to comment on the
need for subsequent modification of the trial protocol for
the infusion. An infusion rate modification should be rec-
ommended if there is strong evidence of a response to the
bolus which is not sustained by the infusion. An interim
analysis at this stage will also be used to stop the trial if
there is very strong evidence for efficacy. We have a 95%
power to detect a 60% treatment effect over the expected
placebo response of 15% without any loss of power for the
overall study (α = 0.001, β = 0.95, missing data/dropouts
10%). If such a major response is noted the IDMEC will
instruct the trial team to stop the trial.
Ethics
This study is approved by the ethics research committee
of University of Peradeniya and the Human Research Eth-
ics Committee of the Australian National University.
Written informed consent will be obtained from all
patients in their native language (Sinhala or Tamil).
Discussion
If FDP is proven to be effective, it will be a very useful
treatment as this treatment is inexpensive and can be
made readily available in rural hospitals of South Asia
where poisoning with oleander seeds is very common[1-
3]. There are no affordable alternative proven treatments
for established arrhythmias for oleander poisoning.
Currently yellow oleander poisoning patients are man-
aged with initial gastric decontamination methods such
as gastric lavage, and activated charcoal, and adminis-
tered atropine or occasionally isoprenaline to increase the
heart rate. Anti-digoxin antibodies have proven to be
effective [18] but are now prohibitively expensive for
developing countries [19,20] and these are not available
in Sri Lankan hospitals.
Clinical benefit of charcoal administration as a decon-
tamination method has some conflicting results. Two
methodologically different randomised control trials
published so far have reported conflicting evidence of its
benefit. De Silva et al in their double blind randomised
control trial reported that multiple doses of activated
charcoal (MDAC) 50 g 6 hourly for 72 hours reduced
mortality and occurrence of life-threatening arrhyth-
mias[21]. In contrast Eddleston et al reported no reduc-
tion in mortality in the subgroup of oleander patients (n =
1647) who were treated with either single dose of acti-
vated charcoal (SDAC) or MDAC or no activated char-
coal[22]. It would be very difficult to draw a definite
conclusion on the efficacy of MDAC based on substantial
difference between these two RCTs [19].
Atropine is the most widely used agent in treating ole-
ander induced bradyarrhythmias [1]. However there is no
evidence of any benefit of atropine in such conditions
[23]. Patients with slow heart rate (below 40 beats/min-
utes) are also routinely transferred to tertiary hospital
where the facilities for transvenous cardiac pacing are
available. However there has been no clinical trial to eval-
uate the effectiveness of this intervention and many
patients die despite pacing [19].
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